Skip to main content
. 2010 May 15;1(1):22–33. doi: 10.18632/oncotarget.105

Fig. 2. CKS1B over-expression promotes myeloma cell drug-resistance.

Fig. 2

(A) Western blots examined CKS1B proteins increased in CKS1B-transfected OCI-MY5 and XG-1 cells (CKS1B-OE). (B - G) MM cells overexpressed CKS1B showed multi-drug resistance. CKS1B-over-expressing OCI-MY5 and XG-1 cells were treated with bortezomib (Vel; 5 nM), doxorubicin (Dox; 100 nM), and etoposide (Epo; 100 nM) for 48 hours in the cultures, and cell growth (B, OCI-MY5: 0.11M vs. 0.75M, and XG1: 0.06M vs. 0.65M; D, OCI:-MY5: 0.11M vs. 0.47M, and XG1: 0.19M vs. 0.54M; F, OCI-MY5: 0.21 vs. 0.39M, and XG1: 0.19 vs. 0.47M) and death (C,OCI-MY5: 34% vs. 63%, and XG1: 20% vs. 54%; E, OCI-MY5: 38% vs. 77%, and XG1: 53% vs. 81%; G, OCI-MY5: 41% vs. 71%, and XG1: 32% vs. 59%) were evaluated for these three treatments respectively. Untreated and EV cells with or without drug treatment were used as controls. Results were expressed as Mean+SD of three independent experiments (*p <0 .05).